PHD inhibitor compounds, compositions, and use

A compound of Formula I:

• or a pharmaceutically acceptable salt thereof, wherein:
• X is N or CR1a;
• Y and Z are independently CH or N;
• A is C1-3 alkyl or C3-6 cycloalkyl;
• R1, each time taken, is independently selected from the group consisting of hydrogen, halogen, CN, OH, C1-3 alkyl optionally substituted one or more halogens, and C1-3 alkoxy;
• R1a is H, CN, halogen, C1-3 alkoxy, OH, or C1-3 alkyl optionally substituted with CN;
• R2, each time taken, is independently selected from the group consisting of hydrogen, halogen, NR4R5, OH, C1-3 alkyl, and C3-6 cycloalkyl;
• R3 is SO2R6, SOR7R8, SOR9, NHR11, or POR12R13;
• R4 and R5 are each independently H or C1-3 alkyl;
• R6 is C1-3 alkyl, NHCOR15, NR16R17, or phenyl;
• R7 is C1-3 alkyl, C3-5 cycloalkyl, phenyl, or NR18R19;
• R8 is NH, NCN, or NCH3;
• R9 is C1-3 alkyl;
• R11 is COR21 or SO2R22;
• R12 and R13 are each independently C1-3 alkyl;
• R15 is C1-3 alkyl;
• R16 and R17 are each independently H, C1-3 alkyl, aryl, cycloalkyl, or wherein R16 and R17 together with the carbon to which they are attached form a heterocycloalkyl;
• R18 and R19 are each independently H or C1-3 alkyl;
• R21 is heterocycloalkyl, cycloalkyl, or C1-3 alkyl;
• R22 is NR23R24 or C1-3 alkyl optionally substituted with carboxyl;
• R23 and R24 are each independently H or C1-3 alkyl;
• m is 1, 2, 3, or 4;
• and
• n is 0, 1, 2 or 3.